Geron to Present at the J.P. Morgan Healthcare Conference

* Reuters is not responsible for the content in this press release.

Thu Jan 5, 2012 7:31am EST

MENLO PARK, Calif., January 5, 2012 - Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chief Executive Officer, will present a company update at 8:00 a.m. PST on Wednesday, January 11, 2012, at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

A live webcast of the audio and slide presentation will be available at http://jpmorgan.metameetings.com/webcasts/healthcare12/directlink?ticker=GERN. Following the live presentation, the webcast will be archived and available for replay at the same address for a period of 30 days.

About Geron

Geron is a biopharmaceutical company developing first-in-class cancer therapeutics. Imetelstat, the company's lead telomerase inhibitor, is currently being evaluated in four Phase 2 clinical oncology studies for the following indications: non-small cell lung cancer, breast cancer, essential thrombocythemia and multiple myeloma. GRN1005, an LRP-directed peptide-drug conjugate, is being evaluated in two Phase 2 clinical trials, one for brain metastases arising from non-small cell lung cancer and the other for brain metastases arising from breast cancer. For more information about the Company, visit www.geron.com.

CONTACT:

Anna Krassowska, Ph.D.
Investor and Media Relations
650-473-7765
info@geron.com

###




This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Geron Corp. via Thomson Reuters ONE
HUG#1575282
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.